SEC Filing Summary: Salarius Pharmaceuticals, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Salarius Pharmaceuticals, Inc. on April 10, 2020, reporting an event that occurred on April 9, 2020. The registrant is an emerging growth company incorporated in Delaware, with its common stock (Symbol: SLRX) listed on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a regulatory compliance issue regarding the company's stock price.
Material Changes and Events
- Delisting Notice: On April 9, 2020, the Company received a notice from Nasdaq stating that the average closing price of its common stock fell below the $1.00 per share minimum bid requirement over the prior 30 consecutive trading days.
- Compliance Period: The Company has been granted an initial 180 calendar days to regain compliance.
- Compliance Criteria: To maintain listing, the closing bid price must be at least $1.00 per share for a minimum of ten consecutive business days within the 180-day period.
- Secondary Period: If the initial period is unsuccessful, the Company may be eligible for an additional 180-day period, provided it meets other listing standards (such as market value of publicly held shares) and notifies Nasdaq of its intent to cure the deficiency.
Outlook, Risks, and Management Commentary
Management intends to actively monitor the closing bid price and evaluate available options to regain compliance. The filing explicitly states there can be no assurance that the Company will be able to regain compliance with the Minimum Bid Requirement or maintain other listing requirements. Failure to cure the deficiency could result in delisting, though the Company retains the right to appeal any delisting determination to a Hearings Panel.
Investor Verification Checklist
- Verify the current trading price of SLRX to assess proximity to the $1.00 threshold.
- Monitor the 30-day average closing price to determine if the 10-day compliance window has been met.
- Review subsequent filings for any announcements regarding reverse stock splits or other capital structure changes intended to address the bid price deficiency.
- Check for any updates on the Company's market value of publicly held shares, which is a prerequisite for the second compliance period.